MSD reintegrates vaccines division into its portfolio

Lucerne, 3rd January 2017 - After the dissolution of the joint venture Sanofi Pasteur MSD (SPMSD) at the end of December 2016, MSD has reintegrated the vaccine division in its portfolio and has been managing its vaccines for children, young people and adults since the beginning of January 2017.

SPMSD has been responsible for access to important vaccines in 19 European countries for more than 20 years and has significantly shaped the high-quality provision of vaccines in Switzerland. Numerous new vaccines from the pipelines of Sanofi Pasteur and MSD have helped during this time to protect millions of people’s lives. As announced in the previous year, Sanofi Pasteur and MSD terminated their joint venture at the end of December 2016. The vaccines were split between the two companies and transferred to the portfolios of the companies.

“We are pleased to reintegrate vaccines in our portfolio and to further strengthen our position as a leading health care company. Our vaccines have contributed in making highly contagious diseases such as measles a rare occurrence today and in preventing diseases caused by HPV such as cervical cancer, anal cancer and genital warts. We are proud to build on the success of Sanofi Pasteur MSD and will continue to focus on improving the vaccine supply and public health in the field of prevention in the future”, says Dr. Thomas Lang, Managing Director MSD Switzerland.

MSD researchers have been committed to vaccines for more than 100 years. Over 30 vaccine developments can thus be traced back to Dr. Maurice Ralph Hilleman (1919 – 2005), including the well-known ones for measles, mumps and hepatitis B. He produced these during his almost 30 years of service for MSD. The MSD portfolio today includes vaccines for infants and small children, young people and adults. The vaccine candidates against Ebola, herpes zoster and pneumococcus are currently in phases II and III in our global clinical research programs. (Status as of December 2016)

More information is available at:

Press contact:
Dr. Angelika März, Director Policy & Communications
MSD Merck Sharp & Dohme AG
Tel. +41 58 618 35 18 / Mobile 079 378 02 47

© 2017 MSD Merck Sharp & Dohme AG, Werftestrasse 4, 6005 Luzern. All rights reserved.